An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease

References

• Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646–656.
   PubMed Web of Science ®Google Scholar
• Brandt KD, Radin EL, Dieppe PA, et al. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis. 2006;65:1261– 1264.
   PubMed Web of Science ®Google Scholar
• Herrero-Beaumont G, Roman-Blas JA, Castaneda S, et al. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum. 2009;39:71–80.
   PubMed Web of Science ®Google Scholar
• Guilak F. Biomechanical factors in osteoarthritis. Best Pract Res Clin Rheumatol. 2011;25:815–823.
   PubMed Web of Science ®Google Scholar
• Williams CJ, Jimenez SA. Skeletal dysplasias and the osteoarthritic phenotype. Best Pract Res Clin Rheumatol. 2003;17:1005–1018.
   PubMed Web of Science ®Google Scholar
• Valdes AM, Spector TD. The contribution of genes to osteoarthritis. Rheum Dis Clin North Am. 2008;34:581–603.
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Castaneda S, Largo R, et al. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11:241.
   PubMed Web of Science ®Google Scholar
• Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment – a systematic approach. Osteoarthritis Cartilage. 2008;16:533–541.
   PubMed Web of Science ®Google Scholar
• Bellido M, Lugo L, Roman-Blas JA, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res Ther. 2010;12:R152.
   PubMed Web of Science ®Google Scholar
• Sniekers YH, Weinans H, Van Osch GJ, et al. Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis. Arthritis Res Ther. 2010;12:R182.
   PubMed Web of Science ®Google Scholar
• Felson DT, Zhang Y, Hannan MT, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1995;38:1500–1505.
   PubMed Web of Science ®Google Scholar
• Srikanth VK, Fryer JL, Zhai G, et al. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13:769–781.
   PubMed Web of Science ®Google Scholar
• Sowers MR, McConnell D, Jannausch M, et al. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum. 2006;54:2481–2487.
   PubMed Web of Science ®Google Scholar
• Spector TD, Nandra D, Hart DJ, et al. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Dis. 1997;56:432–444.
   PubMed Web of Science ®Google Scholar
• Wluka AE, Davis SR, Bailey M, et al. Users of oestrogen replacement therapy have more knee cartilage than non-users. Ann Rheum Dis. 2001;60:332–336.
   PubMed Web of Science ®Google Scholar
• Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;50:3516–3525.
   PubMed Web of Science ®Google Scholar
• Loeser RF Jr. Aging cartilage and osteoarthritis—what’s the link? Sci Aging Knowledge Environ. 2004;29:pe31.
   Google Scholar
• Loeser RF. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 2006;54:1357–1360.
   PubMed Web of Science ®Google Scholar
• Zhuo Q, Yang W, Chen J, et al. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8:729–737.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage. 2012;20:1217–1226.
   PubMed Web of Science ®Google Scholar
• Gomez R, Villalvilla A, Largo R, et al. TLR4 signalling in osteoarthritis: finding targets for candidate DMOADs. Nat Rev Rheumatol. 2015;11:159–170.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Roman-Blas JA, Largo R, et al. Osteoarthritis: a progressive disease with changing phenotypes. Rheumatology (Oxford). 2014;53:1–3.
   PubMed Web of Science ®Google Scholar
• Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386:376–387.
   PubMed Web of Science ®Google Scholar
• Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012;8:665–673.
   PubMed Web of Science ®Google Scholar
• Funck-Brentano T, Cohen-Solal M. Subchondral bone and osteoarthritis. Curr Opin Rheumatol. 2015;27:420–426.
   PubMed Web of Science ®Google Scholar
• Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625–635.
   PubMed Web of Science ®Google Scholar
• Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21:16–21.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Dickson J, Grant RL. Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. Bmj. 2008;336:502–503.
   PubMed Web of Science ®Google Scholar
• Alvarez-Soria MA, Largo R, Santillana J, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis. 2006;65:998–1005.
   PubMed Web of Science ®Google Scholar
• Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, et al. Long term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage. 2008;16:1484–1493.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. Standing committee for international clinical studies including therapeutic trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155.
   PubMed Web of Science ®Google Scholar
• McCarberg B, Tenzer P. Complexities in the pharmacologic management of osteoarthritis pain. Curr Med Res Opin. 2013;29:539–548.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4:605–621.
   PubMedGoogle Scholar
• Bhala N, Emberson J, et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• Katz JA. COX-2 inhibition: what we learned–a controversial update on safety data. Pain Med. 2013;14:S29–S34.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Borzak S, Bjorkman DJ. Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making. Expert Rev Cardiovasc Ther. 2014;12:291–293.
   PubMedGoogle Scholar
• Tehrani M, Aguiar M, Katz JD. Narcotics in rheumatology. Health Serv Insights. 2013;6:39–45.
   PubMedGoogle Scholar
• Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Rheumatol Rep. 2009;11:5–14.
   PubMedGoogle Scholar
• Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007;15:957–965.
   PubMed Web of Science ®Google Scholar
• Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4Suppl):S3–S11.
   Google Scholar
• Davies PS, Graham SM, MacFarlane RJ, et al. Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation. Expert Opin Investig Drugs. 2013;22:423–441.
   PubMed Web of Science ®Google Scholar
• Kongtharvonskul J, Anothaisintawee T, McEvoy M, et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015;20:24.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Martel-Pelletier J, Monfort J, et al.; on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, noninferiority trial versus celecoxib. Ann Rheum Dis. 2016;75:37–44.
   PubMed Web of Science ®Google Scholar
• Roman-Blas JA, Castaneda S, Largo R, et al. An OA phenotype may obtain major benefit from bone-acting agents. Semin Arthritis Rheum. 2014;43:421–428.
   PubMed Web of Science ®Google Scholar
• Tu G, Xu W, Huang H, et al. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem. 2008;15:1388–1395.
   PubMed Web of Science ®Google Scholar
• Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol. 2008;20:269–275.
   PubMed Web of Science ®Google Scholar
• Bursavich MG, Gilbert AM, Lombardi S, et al. Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (aggrecanase-2). Bioorg Medicin Chem Lett. 2007;17:1185–1188.
   PubMed Web of Science ®Google Scholar
• Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013;9:400–410.
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage 2015;23(Suppl 1):S8–S17.
   Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014;74:619–626.
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Biologic basis of osteoarthritis: state of the evidence. Curr Opin Rheumatol. 2015;27:289–294.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Sheu ML, Tsai KS. Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via toll-like receptor-4 and receptor for advanced glycation end products. PLoS ONE. 2013;8:e66611.
   PubMed Web of Science ®Google Scholar
• Vasheghani F, Monemdjou R, Fahmi H, et al. Adult cartilage-specific peroxisome proliferator-activated receptor γ knockout mice exhibit the spontaneous osteoarthritis phenotype. Am J Pathol. 2013;182:1099–1106.
   PubMed Web of Science ®Google Scholar
• Largo R, Diez-Ortego I, Sanchez-Pernaute O, et al. EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Ann Rheum Dis. 2004;63:1197–1204.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhu F, Konstantopoulos K. Interleukin-6 synthesis in human chondrocytes is regulated via the antagonistic actions of prostaglandin (PG)E2 and 15-deoxy-[12,14-PGJ2. PLoS ONE. 2011;6:e27630.
   Google Scholar
• Juarranz Y, Gutierrez-Canas I, Arranz A, et al. VIP decreases TLR4 expression induced by LPS and TNF-α treatment in human synovial fibroblasts. Ann NY Acad Sci. 2006;1070:359–364.
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein B, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759–770.
   PubMed Web of Science ®Google Scholar
• Villalvilla A, da Silva JA, Largo R, et al. 6-Shogaol inhibits chondrocytes’ innate immune responses and cathepsin-K activity. Mol Nutr Food Res. 2014;58:256–266.
   PubMed Web of Science ®Google Scholar
• Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double blind, placebo-controlled study. Arthritis Rheum. 2009;61:344–352.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone. 2012;51:297–311.
   PubMed Web of Science ®Google Scholar
• Hellio Le Graverand MP, Clemmer RS, Redifer P, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013;72:187–195.
   PubMed Web of Science ®Google Scholar
• Henrotin Y, Clutterbuck AL, Allaway D, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage. 2010;18:141–149.
   PubMed Web of Science ®Google Scholar
• Singh R, Ahmed S, Islam N, et al. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. Arthritis Rheum. 2002;46:2079–2086.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33–42.
   PubMed Web of Science ®Google Scholar
• Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis. 2009;68:1078–1079.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Yang S, Shin Y, et al. Interleukin-6 plays an essential role in hypoxia-inducible factor 2α-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 2011;63:2732–2743.
   PubMed Web of Science ®Google Scholar
• Porée B, Kypriotou M, Chadjichristos C, et al. Interleukin-6 (IL-6. and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem. 2008;283:4850–4865.
   PubMed Web of Science ®Google Scholar
• Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum. 2009;60:2037–2045.
   PubMed Web of Science ®Google Scholar
• Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010;18:1441–1447.
   PubMed Web of Science ®Google Scholar
• Sondergaard BC, Schultz N, Madsen SH, et al. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation—divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthritis Cartilage. 2010;18:279–288.
   PubMed Web of Science ®Google Scholar
• Loeser RF, Erickson EA, Long DL. Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008;20:581–586.
   PubMed Web of Science ®Google Scholar
• Mi M, Shi S, Li T, et al. TIMP2 deficient mice develop accelerated osteoarthritis via promotion of angiogenesis upon destabilization of the medial meniscus. Biochem Biophys Res Commun. 2012;423:366–372.
   PubMed Web of Science ®Google Scholar
• Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of TIMP3(-/-) mice. Arthritis Rheum. 2007;56:905–909.
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG 116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12 month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9:R109.
   PubMed Web of Science ®Google Scholar
• Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo controlled, double-blind trial. Arthritis Rheum. 2005;52:2015–2025.
   PubMed Web of Science ®Google Scholar
• Chockalingam PS, Sun W, Rivera-Bermudez MA, et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011;19:315–323.
   PubMed Web of Science ®Google Scholar
• Troeberg L, Fushimi K, Khokha R, et al. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. Faseb J. 2008;22:3515–3524.
   PubMed Web of Science ®Google Scholar
• Hannan MT, Felson DT, Anderson JJ, et al. Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham Osteoarthritis Study. Arthritis Rheum. 1990;33:525–532.
   PubMed Web of Science ®Google Scholar
• Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum. 1999;42:17–24.
   PubMed Web of Science ®Google Scholar
• Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum. 1998;41:1867–1873.
   PubMed Web of Science ®Google Scholar
• De Klerk BM, Schiphof D, Groeneveld FP, et al. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review. Rheumatology (Oxford). 2009;48:104–112.
   PubMed Web of Science ®Google Scholar
• Maheu E, Dreiser RL, Guillou GB, et al. Hand osteoarthritis patients characteristics according to the existence of a hormone replacement therapy. Osteoarthritis Cartilage. 2000;Suppl A:S33–S37.
   Google Scholar
• Lugo L, Villalvilla A, Largo R, et al. Selective estrogen receptor modulators (SERMs): new alternatives for osteoarthritis? Maturitas. 2014;77:380–384.
   PubMed Web of Science ®Google Scholar
• Tsai CL, Liu TK. Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sci. 1992;50:1943–1951.
   PubMed Web of Science ®Google Scholar
• Colombo C, Butler M, Hickman L, et al. A new model of osteoarthritis in rabbits II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemically. Arthritis Rheum. 1983;26:1132–1139.
   PubMed Web of Science ®Google Scholar
• Christgau S, Tanko LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause. 2004;11:508–518.
   PubMed Web of Science ®Google Scholar
• Høegh-Andersen P, Tankó LB, Andersen TL, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validationand application. Arthritis Res Ther. 2004;6:R169–80.
   PubMed Web of Science ®Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther. 2005;7:R625–R633.
   PubMed Web of Science ®Google Scholar
• Bingham CO 3rd, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494–3507.
   PubMed Web of Science ®Google Scholar
• Buckland-Wright JC, Messent EA, Bingham CO 3rd, et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford). 2007;46:257–264.
   PubMed Web of Science ®Google Scholar
• Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012;71:1322–1328.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Alexandersen P, et al. CSMC021C2301/2 investigators. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthritis Cartilage. 2015;23:532–543.
   PubMed Web of Science ®Google Scholar
• Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage. 2011;19:1228–1236.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2013;72:179–186.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Roman-Blas JA, Largo R, et al. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol. 2012;83:315–323.
   PubMed Web of Science ®Google Scholar
• Strand V, McIntyre LF, Beach WR, et al. Safety and efficacy of US approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res. 2015;8:217–228.
   PubMed Web of Science ®Google Scholar
• Maheu E, Rannou F, Reginster JY. Efficacy and safety of hyaluronic acid in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S28–S33.
   PubMed Web of Science ®Google Scholar
• Campbell KA, Erickson BJ, Saltzman BM, et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: a systematic review of overlapping meta-analyses. Arthroscopy. 2015;31:2036–2045.
   PubMed Web of Science ®Google Scholar
• Richette P, Chevalier X, Ea HK. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open. 2015;1:e000071.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis–meta-analysis. Osteoarthritis Cartilage. 2011;19:611–619.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162:46–54.
   PubMed Web of Science ®Google Scholar
• Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med. 2015;372:1040–1047.
   PubMed Web of Science ®Google Scholar
• Navarro-Sarabia F, Herrero-Beaumont G. Viscosupplementation for osteoarthritis of the knee. Ann Intern Med. 2013;58:74–75.
   Web of Science ®Google Scholar
• Rutjes AW, Juni P, Da Costa BR, et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180–191.
   PubMed Web of Science ®Google Scholar
• Jevsevar D, Donnelly P, Brown GA, et al. Viscosupplementation for osteoarthritis of the knee: a systematic review of the evidence. J Bone Joint Surg Am. 2015;97(24):2047–2060.
   PubMed Web of Science ®Google Scholar
• Migliore A, Bizzi E, Herrero-Beaumont G, et al. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap! Eur Rev Med Pharmacol Sci. 2015;19:1124–1129.
   PubMed Web of Science ®Google Scholar
• Brown GA. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013;21:577–579.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of non-pharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64:465–474.
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22:363–388.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253–263.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, McAlindon TE, Sullivan MC, et al. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann Intern Med. 2015;163:365–372.
   PubMed Web of Science ®Google Scholar
• Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67:1716–1723.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zou K, Doherty M. Placebos for knee osteoarthritis: reaffirmation of “Needle Is Better Than Pill”. Ann Intern Med. 2015;163:392–393.
   PubMed Web of Science ®Google Scholar
• Forogh B, Mianehsaz E, Shoaee S, et al. Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: a double-blind randomized clinical trial. J Sports Med Phys Fitness. 2015. Jul 14. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Raeissadat SA, Rayegani SM, Hassanabadi H, et al. Knee osteoarthritis injection choices: platelet- rich plasma (PRP) versus hyaluronic acid (A one year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:1–8.
   PubMed Web of Science ®Google Scholar
• Meheux CJ, McCulloch PC, Lintner DM, et al. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy. 2015. pii: S0749-8063(15)00659-3.
   PubMed Web of Science ®Google Scholar
• Rabago D, Patterson JJ, Mundt M, et al. Dextrose and morrhuate sodium injections (prolotherapy) for knee osteoarthritis: a prospective open label trial. J Altern Complement Med. 2014;20:383–391.
   PubMed Web of Science ®Google Scholar
• Yang KG, Raijmakers NJ, van Arkel ER, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthr Cartil. 2008;16:498–505.
   PubMed Web of Science ®Google Scholar
• Baltzer AW, Moser C, Jansen SA, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009;17:152–160.
   PubMed Web of Science ®Google Scholar
• Baltzer AW, Ostapczuk MS, Stosch D, et al. A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum. Orthop Rev (Pavia). 2013;5:59–64.
   PubMedGoogle Scholar
• Hunter DJ, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2010;11:232.
   PubMed Web of Science ®Google Scholar
• Ellsworth JL, Berry J, Bukowski T, et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage. 2002;10:308–320.
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Hellot S, Dreher D, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:1820–1831.
   PubMed Web of Science ®Google Scholar
• Diekman BO, Guilak F. Stem cell-based therapies for osteoarthritis: challenges and opportunities. Curr Opin Rheumatol. 2013;25:119–126.
   PubMed Web of Science ®Google Scholar
• Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32:1254–1266.
   PubMed Web of Science ®Google Scholar
• Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA. 1993;90:0764–8.
   Google Scholar
• Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol. 1999;154:1159–1169.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yu C, Xushi ZC, et al. Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. Biochem Biophys Res Commun. 2006;341:202–208.
   PubMed Web of Science ®Google Scholar
• Chen B, Qin J, Wang H, et al. Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med. 2010;42:684–695.
   PubMed Web of Science ®Google Scholar
• Watson RS, Broome TA, Levings PP, et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 2013;20:670–677.
   PubMed Web of Science ®Google Scholar
• Ha CW, Noh MJ, Choi KB, et al. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 2012;14:247–256.
   PubMed Web of Science ®Google Scholar
• Ha CW, Cho JJ, Elmallah RK, et al. A multicenter, single-blind, phase iia clinical trial to evaluate the efficacy and safety of a cell-mediated gene therapy in degenerative knee arthritis patients. Hum Gene Ther Clin Dev. 2015;26:125–130.
   PubMed Web of Science ®Google Scholar
• Lawrence A, Xu X, Bible MD, et al. Synthesis and characterization of a lubricin mimic (mLub) to reduce friction and adhesion on the articular cartilage surface. Biomaterials. 2015;73:42–50.
   PubMed Web of Science ®Google Scholar
• Iqbal SM, Leonard C, Regmi CS, et al. Lubricin/Proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep. 2016;6:18910.
   PubMed Web of Science ®Google Scholar
• Ludwig TE, McAllister JR, Lun V, et al. Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: restoration through proteoglycan 4 supplementation. Arthritis Rheum. 2012;64:3963–3971.
   PubMed Web of Science ®Google Scholar
• Elsaid KA, Zhang L, Waller K, et al. The impact of forced joint exercise on lubricin biosynthesis from articular cartilage following ACL transection and intra-articular lubricin’s effect in exercised joints following ACL transection. Osteoarthritis Cartilage. 2012;20:940–948.
   PubMed Web of Science ®Google Scholar
• Herrero-Beaumont G, Guerrero R, Sánchez-Pernaute O, et al. Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee. Clin Chim Acta. 2001;308:107–115.
   PubMed Web of Science ®Google Scholar